Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Innate Pharma (IPHA) Debt Ratio (2017 - 2025)

Historic Debt Ratio for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to 0.29.

  • Innate Pharma's Debt Ratio rose 2410.24% to 0.29 in Q2 2025 from the same period last year, while for Jun 2025 it was 0.29, marking a year-over-year increase of 2410.24%. This contributed to the annual value of 0.28 for FY2024, which is 2255.84% up from last year.
  • Latest data reveals that Innate Pharma reported Debt Ratio of 0.29 as of Q2 2025, which was up 2410.24% from 0.28 recorded in Q4 2024.
  • Over the past 5 years, Innate Pharma's Debt Ratio peaked at 0.29 during Q2 2025, and registered a low of 0.06 during Q2 2021.
  • In the last 5 years, Innate Pharma's Debt Ratio had a median value of 0.2 in 2023 and averaged 0.2.
  • Within the past 5 years, the most significant YoY rise in Innate Pharma's Debt Ratio was 16644.31% (2021), while the steepest drop was 972.45% (2021).
  • Quarter analysis of 5 years shows Innate Pharma's Debt Ratio stood at 0.17 in 2021, then increased by 22.87% to 0.2 in 2022, then grew by 12.03% to 0.23 in 2023, then increased by 22.56% to 0.28 in 2024, then grew by 4.21% to 0.29 in 2025.
  • Its Debt Ratio was 0.29 in Q2 2025, compared to 0.28 in Q4 2024 and 0.23 in Q2 2024.